阻断CD47-SIRPα轴：一种有前景的癌症免疫治疗方法。 - Suppr

Suppr

超能文献

Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy.

作者信息

Uger Robert, Johnson Lisa

机构信息

Trillium Therapeutics Inc., Mississaugua, Ontario, Canada.

Translational Research, Trillium Therapeutics Inc., Mississaugua, Ontario, Canada.

出版信息

Expert Opin Biol Ther. 2020 Jan;20(1):5-8. doi: 10.1080/14712598.2020.1685976. Epub 2019 Nov 5.

DOI:10.1080/14712598.2020.1685976

PMID:31663384

Abstract

摘要

相似文献

Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy.阻断CD47-SIRPα轴：一种有前景的癌症免疫治疗方法。

Expert Opin Biol Ther. 2020 Jan;20(1):5-8. doi: 10.1080/14712598.2020.1685976. Epub 2019 Nov 5.

Cancer immunotherapy targeting the CD47/SIRPα axis.靶向CD47/SIRPα轴的癌症免疫疗法。

Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10.

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.靶向CD47-SIRPα信号轴：B细胞淋巴瘤免疫治疗的当前研究

J Int Med Res. 2018 Nov;46(11):4418-4426. doi: 10.1177/0300060518799612. Epub 2018 Sep 18.

Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.阻断 CD47 联合抗 CD20 消除犬弥漫性大 B 细胞淋巴瘤的小鼠异种移植模型

Cancer Immunol Res. 2016 Dec;4(12):1072-1087. doi: 10.1158/2326-6066.CIR-16-0105. Epub 2016 Nov 14.

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.CD47-SIRPα信号轴作为癌症中的一种固有免疫检查点。

Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.ADU-1805 是一种选择性的全等位基因抗 SIRPα 抗体，可阻断 SIRPα-CD47 固有免疫检查点，对其功能进行了鉴定。

J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0.

Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.外泌体-SIRPα，阻断 CD47 可增强癌细胞吞噬作用。

Biomaterials. 2017 Mar;121:121-129. doi: 10.1016/j.biomaterials.2017.01.004. Epub 2017 Jan 3.

SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.SIRPα-CD47 免疫检查点阻断在癌症治疗中的应用。

Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11.

Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.单独阻断 CD47-SIRPα 轴或联合自噬耗竭用于胶质母细胞瘤的治疗。

Carcinogenesis. 2018 May 3;39(5):689-699. doi: 10.1093/carcin/bgy041.

SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.SIRPα 抗体融合蛋白选择性结合并消除双抗原表达肿瘤细胞。

Clin Cancer Res. 2016 Oct 15;22(20):5109-5119. doi: 10.1158/1078-0432.CCR-15-2503. Epub 2016 Apr 28.

引用本文的文献

Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy.用于癌症治疗的靶向信号调节蛋白α（SIRPα）和磷脂酶A2G7（PLA2G7）的全人源抗体的开发。

Antibodies (Basel). 2025 Mar 3;14(1):21. doi: 10.3390/antib14010021.

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.联合 CD38 抗体和 CD47 阻断是治疗表达 CD38 的血液系统恶性肿瘤的一种有前途的策略。

Front Immunol. 2024 Jun 25;15:1398508. doi: 10.3389/fimmu.2024.1398508. eCollection 2024.

"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.“找我”和“吃我”信号：用于调节抗肿瘤免疫的吞噬过程的工具。

Cancer Commun (Lond). 2024 Jul;44(7):791-832. doi: 10.1002/cac2.12579. Epub 2024 Jun 23.

Pan-cancer analysis for the prognostic and immunological role of CD47: interact with TNFRSF9 inducing CD8 + T cell exhaustion.CD47预后和免疫作用的泛癌分析：与TNFRSF9相互作用诱导CD8 + T细胞耗竭。

Discov Oncol. 2024 May 8;15(1):149. doi: 10.1007/s12672-024-00951-z.

The cross-talk between macrophages and tumor cells as a target for cancer treatment.巨噬细胞与肿瘤细胞之间的相互作用作为癌症治疗的靶点。

Front Oncol. 2023 Nov 14;13:1259034. doi: 10.3389/fonc.2023.1259034. eCollection 2023.

The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.抗 CD47 抗体的抗肿瘤活性需要 Fc-FcγR 相互作用。

Cancer Cell. 2023 Dec 11;41(12):2051-2065.e6. doi: 10.1016/j.ccell.2023.10.007. Epub 2023 Nov 16.

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy.靶向CD47-SIRPα轴用于霍奇金淋巴瘤和非霍奇金淋巴瘤的免疫治疗

Genes Dis. 2023 Jan 11;11(1):205-217. doi: 10.1016/j.gendis.2022.12.008. eCollection 2024 Jan.

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions.抗CD47抗体的抗肿瘤活性需要Fc-FcγR相互作用。

bioRxiv. 2023 Jun 29:2023.06.29.547082. doi: 10.1101/2023.06.29.547082.

Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment.癌症干细胞与促肿瘤炎症微环境的关系

Biomedicines. 2023 Jan 11;11(1):189. doi: 10.3390/biomedicines11010189.

Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy.利用双特异性纳米生物缀合物进行癌症免疫治疗以实现实体瘤的免疫转化。

Nat Nanotechnol. 2022 Dec;17(12):1332-1341. doi: 10.1038/s41565-022-01245-7. Epub 2022 Nov 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验